Testing a blood thinner plan during pregnancy
Part of Blood & lymphatic, Women’s health & pregnancy clinical trials.
This study looks at how people’s blood and clotting behave during pregnancy when taking a specific blood thinner called low molecular weight heparin (LMWH) three times a day. It may help doctors fine-tune how safely and effectively LMWH is used during pregnancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant and your baby is one (single) baby in the uterus
- Your doctor has told you that you need full-dose LMWH during pregnancy
- You are 18 years old or older
- You have not had heparin-induced thrombocytopenia (HIT) in the past
- You are not allergic to enoxaparin (a common LMWH)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the best way to manage blood thinners (like injections of LMWH) during pregnancy for people who need them because of a past or current blood clot risk. It may help by improving how safely and effectively anticoagulation is handled to reduce clot complications.
This trial tests whether a blood-thinning medication (enoxaparin) can help prevent complications like preterm birth or preeclampsia from happening again. It is for people who had a past pregnancy problem tied to placenta blood flow issues.
This study looks at how blood clotting changes during pregnancy and how a common blood thinner affects clotting in the lab. It may help doctors understand pregnancy-related clotting risks better.
This trial is testing a short course of a low-dose blood thinner (heparin) to prevent dangerous blood clots in the legs or lungs after childbirth. It is for women who have certain risk factors that make clots more likely.
This study tests whether giving a short course of a daily blood-thinning injection (enoxaparin) after childbirth can safely prevent blood clots in women at intermediate risk. If you qualify, you would receive the injection or a placebo (inactive shot) for up to 5 days while in the hospital.
This study looks at pregnancy-related risk for a dangerous blood clot in the leg or lung (venous thromboembolism). It focuses on pregnant people who already have a higher-than-average risk and wants to see how to manage that risk safely.
Hear when a new Pregnancy, High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.